We’re delighted to add our latest Educational Series on selpercatinib for the treatment of advanced RET fusion-positive NSCLC.
The review provides an update on RET fusion-positive NSCLC, with a focus on testing for RET fusions, and treatment with the selective RET inhibitor selpercatinib. It also includes guiding commentary from Dr Malinda Itchins, Thoracic Medical Oncologist at Royal North Shore Hospital, North Shore Private and Genesis Care St Leonards.
Please login below to download this issue (PDF)